search
Back to results

Diclofenac as a KMO Inhibitor (DKMOI)

Primary Purpose

Alcohol Use Disorder

Status
Not yet recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Diclofenac
Placebo
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Alcohol Use Disorder focused on measuring diclofenac

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Ages 21-65 Meet DSM-5 diagnostic criteria for AUD of any severity (Mild, Moderate, or Severe) Exclusion Criteria: Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants Self-reported daily use of opioids (including prescribed) Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised If female: pregnant, nursing, or with reproductive potential who refuses to use reliable methods of birth control throughout the study Any autoimmune disorder, inflammatory disorder, or medical condition that may interfere with safe study participation and/or study aims (e.g., any cardiac, renal, or liver disease, uncontrolled hypertension, or diabetes) Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year Currently on prescription medication that contraindicates use of diclofenac, including but not necessarily limited to: oral corticosteroids, anticoagulants, lithium, warfarin, aspirin (daily use), methotrexate, cyclosporine, ACE-inhibitors, and diuretics like furosemide and thiazides Previously known hypersensitivity, including gastroenteritis, asthma, and allergic-type reactions, to any NSAID and/or aspirin Current daily use of any NSAID or regular pattern of near daily use within the past three months, regular use of a prebiotic or probiotic supplement and/or any antibiotic, prebiotic, or probiotic use within the last month Any lifetime history of ulcer disease, gastritis, gastroenteritis, or gastrointestinal bleeding Current or recent (within 3 months) participation in a clinical trial involving medication administration Currently in treatment, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment for AUD Current (last 12 months) DSM-5 diagnosis of SUD for any psychoactive substances other than alcohol and nicotine Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders AST and ALT > four times the upper limit of the normal range, or albumin, GFR, BUN, or creatinine 15% > the upper limit of the normal range Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12 Has below a 6th grade reading level Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity

Sites / Locations

  • Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Diclofenac

Placebo

Arm Description

Participants will take a single 100mg dose of diclofenac.

Participants will take a single dose of placebo.

Outcomes

Primary Outcome Measures

Kynurenic Acid
Serum levels of Kynurenic Acid

Secondary Outcome Measures

Full Information

First Posted
August 31, 2023
Last Updated
August 31, 2023
Sponsor
University of Maryland, Baltimore
search

1. Study Identification

Unique Protocol Identification Number
NCT06029296
Brief Title
Diclofenac as a KMO Inhibitor
Acronym
DKMOI
Official Title
Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 2023 (Anticipated)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Maryland, Baltimore

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The primary aim is to assess whether this dose of diclofenac, vs. placebo, increases circulating levels of kynurenic acid. This finding would provide evidence that diclofenac (100 mg) inhibits the kynurenine 3-monooxygenase enzyme.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Use Disorder
Keywords
diclofenac

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Diclofenac
Arm Type
Active Comparator
Arm Description
Participants will take a single 100mg dose of diclofenac.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will take a single dose of placebo.
Intervention Type
Drug
Intervention Name(s)
Diclofenac
Intervention Description
100 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Sugar pill
Primary Outcome Measure Information:
Title
Kynurenic Acid
Description
Serum levels of Kynurenic Acid
Time Frame
0-, 60-, 120-, 180-, and 240-minutes after pill administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages 21-65 Meet DSM-5 diagnostic criteria for AUD of any severity (Mild, Moderate, or Severe) Exclusion Criteria: Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants Self-reported daily use of opioids (including prescribed) Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised If female: pregnant, nursing, or with reproductive potential who refuses to use reliable methods of birth control throughout the study Any autoimmune disorder, inflammatory disorder, or medical condition that may interfere with safe study participation and/or study aims (e.g., any cardiac, renal, or liver disease, uncontrolled hypertension, or diabetes) Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year Currently on prescription medication that contraindicates use of diclofenac, including but not necessarily limited to: oral corticosteroids, anticoagulants, lithium, warfarin, aspirin (daily use), methotrexate, cyclosporine, ACE-inhibitors, and diuretics like furosemide and thiazides Previously known hypersensitivity, including gastroenteritis, asthma, and allergic-type reactions, to any NSAID and/or aspirin Current daily use of any NSAID or regular pattern of near daily use within the past three months, regular use of a prebiotic or probiotic supplement and/or any antibiotic, prebiotic, or probiotic use within the last month Any lifetime history of ulcer disease, gastritis, gastroenteritis, or gastrointestinal bleeding Current or recent (within 3 months) participation in a clinical trial involving medication administration Currently in treatment, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment for AUD Current (last 12 months) DSM-5 diagnosis of SUD for any psychoactive substances other than alcohol and nicotine Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders AST and ALT > four times the upper limit of the normal range, or albumin, GFR, BUN, or creatinine 15% > the upper limit of the normal range Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12 Has below a 6th grade reading level Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Brian Brandler, MA
Phone
410-402-6425
Email
bbrandler@som.umaryland.edu
First Name & Middle Initial & Last Name or Official Title & Degree
AnneMarie Kearns, BS
Phone
410-402-6854
Email
akearns@mprc.umaryland.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Roche, PhD
Organizational Affiliation
University of Maryland, Baltimore
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)
City
Catonsville
State/Province
Maryland
ZIP/Postal Code
21228
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brian Brandler, MA
Phone
410-402-6425
Email
bbrandler@som.umaryland.edu
First Name & Middle Initial & Last Name & Degree
Daniel Roche, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Diclofenac as a KMO Inhibitor

We'll reach out to this number within 24 hrs